ArticleMacromolecular bioscience2026
Synergistic Application of Mesenchymal Stem Cells and Anti-Inflammatory Therapeutics Within Hydrogel Matrices For Enhanced Treatment of Osteoarthritis and Promotion of Cartilage Regeneration.
Article in Macromolecular bioscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Osteoarthritis (OA) is the most prevalent degenerative joint disorder, characterized by chronic joint pain, stiffness, and progressive loss of articular cartilage. To address this, the project developed an inflammatory-targeting drug delivery system to mitigate underlying inflammation. The polyvinyl alcohol (PVA) hydrogel, a crosslinked polymer network with excellent water absorption and retention capabilities, was utilized as the drug carrier platform. The polydopamine (PDA) particles were leveraged to effectively eliminate reactive oxygen species and reduce oxidative stress. Furthermore, R-7050, a cell-permeable triazoline compound, was encapsulated as a TNF-α inhibitor for targeted anti-inflammatory therapy. To enhance therapeutic efficacy, bone marrow mesenchymal stem cells (MSCs) were incorporated into the drug delivery system, which can secrete neurotrophic factors, promote vascular regeneration, and exert superior anti-inflammatory effects. Results have demonstrated that the developed drug delivery system (SC@PDA/PVA-R7050 Gel) could sustain the release of therapeutic agents in the affected joint area, thereby improving the treatment efficacy. The synergistic integration of the PVA hydrogel, PDA, R-7050, and MSCs provides a novel and promising solution for the targeted therapy of osteoarthritis, with significant clinical application potential. (177 words in total).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.